Publication:
EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3

Thumbnail Image

Date

2013

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

Landes Bioscience
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Concha-Benavente, Fernando, Raghvendra M Srivastava, Soldano Ferrone, and Robert L Ferris. 2013. “EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3.” Oncoimmunology 2 (12): e27215. doi:10.4161/onci.27215. http://dx.doi.org/10.4161/onci.27215.

Research Data

Abstract

The epidermal growth factor receptor (EGFR) supports the escape of malignant cells from immunosurveillance by inhibiting the activation of signal transducer and activator of transcription 1 (STAT1) while promoting that of STAT3. We have recently demonstrated that protein tyrosine phosphatase, non-receptor type 11 (PTNP11, best known as SHP2), a phosphatase that operates downstream of EGFR, is responsible for the dephosphorylation of active STAT1 and for the inhibition of the antigen-processing machinery (APM), hence favoring tumor immunoescape. Thus, EGFR signaling may skew the tumor microenvironment to suppress cellular immune responses.

Description

Keywords

APM, EGFR, immunoescape, immunotherapy, pSTAT1, pSTAT3, SHP2

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Referenced By

Related Stories